Oncology-New York最新文献_第2页

Which Treatment for Which Patient: Rectal Cancer Management After PROSPECT Trial. 哪种治疗方法适合哪种患者？PROSPECT 试验后的直肠癌管理。

IF 1.8 4区医学

Oncology-New York Pub Date : 2024-05-13 DOI: 10.46883/2024.25921019

Seth Felder, Jessica Frakes, Manju George, Allison Rosen, Ibrahim Halil Sahin

引用次数: 0

Synchronous Well-Differentiated Papillary Mesothelioma and Endometrioid Adenocarcinoma Arising From Endometriosis. 同步分化良好的乳头状间皮瘤和子宫内膜异位症引发的子宫内膜样腺癌

IF 1.8 4区医学

Oncology-New York Pub Date : 2024-05-13 DOI: 10.46883/2024.25921020

Catherine R Lewis, Jocelyn Uchic-Boccella, Jenna Zimmerman, Eirwen Miller, Sharon Liang, Patrick L Wagner

{"title":"Synchronous Well-Differentiated Papillary Mesothelioma and Endometrioid Adenocarcinoma Arising From Endometriosis.","authors":"Catherine R Lewis, Jocelyn Uchic-Boccella, Jenna Zimmerman, Eirwen Miller, Sharon Liang, Patrick L Wagner","doi":"10.46883/2024.25921020","DOIUrl":"10.46883/2024.25921020","url":null,"abstract":"Well-differentiated papillary mesothelioma (WDPM) is a rare mesothelial tumor of uncertain malignant potential. We present a unique case of a woman with synchronous WDPM and well-differentiated endometrioid adenocarcinoma (EA) arising from extraovarian endometriosis. A 56-year-old postmenopausal woman presented with a several-month history of right lower quadrant abdominal pain. She had a history of supracervical hysterectomy and bilateral salpingo-oophorectomy secondary to endometriosis. Imaging reported a mass in the right lower quadrant originating from the distal ileum. At laparotomy, the patient underwent a right colectomy with resection of the terminal ileum and excision of a solitary peritoneal nodule. Pathology was consistent with a diagnosis of well-differentiated EA (arising from extraovarian endometriosis) and WDPM. Further treatment consisted of complete surgical staging/debulking and adjuvant chemotherapy directed toward metastatic well-differentiated EA. Surgeons should be familiar with WDPM as a potential finding in women of reproductive age undergoing abdominal surgery for any indication.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"38 5","pages":"191-193"},"PeriodicalIF":1.8,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141082511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting. 在资源有限的环境中诊断和治疗痉挛性浆细胞树突状细胞肿瘤。

4区医学

Oncology-New York Pub Date : 2024-03-01 DOI: 10.46883/2024.25921014

Fiza Khan, Foorquan Hashmi, Nerses Ghahramanyan, Elen Baloyan, Gevorg Tamamyan, Marina Konopleva, Naveen Pemmaraju, Astghik Voskanyan

引用次数: 0

Extreme Case of Surgical Port Metastasis in Ovarian Cancer. 卵巢癌手术孔转移的极端病例。

4区医学

Oncology-New York Pub Date : 2024-03-01 DOI: 10.46883/2024.25921015

Michał Kostrzanowski, Grzegorz Ziółkowski, Filip Dąbrowski

引用次数: 0

Rising Prices and Lower Medicare Reimbursement Rates Create Outrage Among Clinicians. 价格上涨和医疗保险报销比例降低引起临床医生的愤怒。

4区医学

Oncology-New York Pub Date : 2024-03-01 DOI: 10.46883/2024.Pubmed Id

Nora Janjan Md Mpsa Mba, Patrick J Silva

引用次数: 0

Rising Prices and Lower Medicare Reimbursement Rates Create Outrage Among Clinicians. 价格上涨和医疗保险报销比例降低引起临床医生的愤怒。

4区医学

Oncology-New York Pub Date : 2024-03-01 DOI: 10.46883/2024.25921016

Nora Janjan Md Mpsa Mba, Patrick J Silva

引用次数: 0

Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma. 推动发现和治疗套细胞淋巴瘤二十年。

4区医学

Oncology-New York Pub Date : 2024-02-05 DOI: 10.46883/2024.25921013

Lymphoma Research Foundation Lymphoma Research Foundation

{"title":"Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma.","authors":"Lymphoma Research Foundation Lymphoma Research Foundation","doi":"10.46883/2024.25921013","DOIUrl":"10.46883/2024.25921013","url":null,"abstract":"Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin lymphoma characterized by the t(11;14) chromosomal translocation, which leads to the dysregulation of the cell cycle through overexpression of cyclin D1. Although advances in treatment have improved outcomes, in particular the introduction of Bruton tyrosine kinase inhibitors to the treatment armamentarium and more recently chimeric antigen receptor T-cell therapy, MCL often rapidly develops resistance and has a high rate of relapse. In addition, MCL is clinically heterogeneous. Response to treatment can vary, making it difficult to establish a standard treatment approach. Thus, there remains a significant need for more research on MCL biology, including those molecular mechanisms underpinning treatment response or lack thereof, so that novel agents may be identified and/or the use of existing agents may be optimized. At the Lymphoma Research Foundation's 20th MCL Scientific Consortium and Workshop, researchers gathered to discuss recent developments in both basic scientific and clinical research to continue to develop an understanding of MCL and improve outcomes for patients. This report, which includes a summary of each presentation, reviews the findings presented at the workshop and highlights opportunities, open questions, and areas for future study that would pave the way for a cure for this disease in the coming decades.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"38 2","pages":"51-67"},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139991790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Building Efficiency and Scaling With a Remote Genetic Counseling Program. 提高远程遗传咨询计划的效率和规模。

4区医学

Oncology-New York Pub Date : 2024-01-09 DOI: 10.46883/2024.25921011

Smita K Rao, L Johnetta Blakely, Kate Small, Stephen Schleicher, Natalie R Dickson Md

{"title":"Building Efficiency and Scaling With a Remote Genetic Counseling Program.","authors":"Smita K Rao, L Johnetta Blakely, Kate Small, Stephen Schleicher, Natalie R Dickson Md","doi":"10.46883/2024.25921011","DOIUrl":"10.46883/2024.25921011","url":null,"abstract":"Purpose A third-party telemedicine (TM) genetic counseling program was initiated at a large community oncology practice spanning 35 clinical sites with 110 clinicians and 97 advanced practice providers throughout Tennessee and Georgia. Patients and Methods Appropriate patients were referred through the electronic health record (EHR) based on current National Comprehensive Cancer Network guidelines. A combination of TM and genetic counseling assistants enhanced convenience, broadened access, and decreased no-show rates. Physician education for mutation-positive screening recommendations was provided through deep integration of dedicated genetic counseling notes in the EHR. Results From 2019 to 2022, the program expanded from 1 to 20 clinics with referrals growing from 195 to 885. An average of 82% of patients completed genetic counseling consultations over TM with more than 70% completing genetic testing. The average was 4 to 6 days from referral to consultation. The no-show rate was maintained at less than 7%. In 2023, this model supported all 35 clinics across the state. Conclusion Our program illustrates how remote genetic counseling programs are an effective choice for scaling genetics care across a large community oncology practice. Deep integration of TM genetic counseling within the EHR helps identify patients who are high risk and improves test adoption, patient keep rate, and turnaround time, helping to achieve better patient outcomes.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"38 1","pages":"20-25"},"PeriodicalIF":0.0,"publicationDate":"2024-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139652146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in Italy. 妇科癌症幸存者的生活经历：在意大利进行的一项调查

4区医学

Oncology-New York Pub Date : 2024-01-09 DOI: 10.46883/2024.25921012

Sonia La Spina, Paolo Scollo, Basilio Pecorino, Valentina Lombardo, Annamaria Motta, Rosa Gioia Calderone, Stefania Calì, Helga Lipari, Giuseppa Scandurra

{"title":"Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in Italy.","authors":"Sonia La Spina, Paolo Scollo, Basilio Pecorino, Valentina Lombardo, Annamaria Motta, Rosa Gioia Calderone, Stefania Calì, Helga Lipari, Giuseppa Scandurra","doi":"10.46883/2024.25921012","DOIUrl":"10.46883/2024.25921012","url":null,"abstract":"Background: The study of health-related quality of life in survivors of gynecologic cancers is becoming increasingly important as 1.5 million survivors of gynecologic cancer in the United States and more are expected due to advances in diagnosis and treatment. This project investigated the perceived needs and lived experiences of survivors of gynecological cancer to help design supportive activities to be implemented in clinical practice.Methods: Patients were recruited in hospitals or through social media and responded to an online survey that was addressed to patients in Italy, specifically in Sicily, Puglia, and Campania. Patients with ovarian, endometrium, or cervix cancer were recruited among women attending Cannizzaro Hospital and Alleanza Contro il Tumore Ovarico (Alliance Against Ovarian Cancer) members.Results: Body image perception was changed in 82.3% of respondents, whereas familial relationships were described as changed by 27.5% of women. In 69.6% of patients, sexual habits were hindered by changes in the body, depression, pain, and awkwardness. Physicians informed patients about sexuality changes related to cancer extensively in 16.7% of cases and briefly in 19.6% of cases. The advice of a clinical sexologist was considered potentially helpful by 31.4% of patients and not potentially helpful by 47.1%, whereas 21.6% of patients had no opinion.Conclusions: Although sexual habits are often changed by cancer, women surviving gynecological cancer rarely seek medical advice in this area. Physicians should be trained to inform patients and to promote referrals to sexologists.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"38 1","pages":"15-19"},"PeriodicalIF":0.0,"publicationDate":"2024-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139652147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early Access to Electronic Health Records May Influence the Patient Experience. 尽早使用电子病历可能会影响患者体验。

4区医学

Oncology-New York Pub Date : 2023-12-14 DOI: 10.46883/2023.25921010

Mehmet Sitki Copur, Soe Min Tun, Adam J Horn

引用次数: 0